BR112015028650A2 - UM ANTÍGENO ISOLADO PARA LEUCOCIDINA DE S. AUREUS, UM ANTICORPO LIGANTE ESPECÍFICO PARA O ANTÍGENO, E UM COMPLEXO CD11b/CD18 HUMANO PARA UTILIZAÇÃO EM UM MÉTODO ANALÍTICO - Google Patents
UM ANTÍGENO ISOLADO PARA LEUCOCIDINA DE S. AUREUS, UM ANTICORPO LIGANTE ESPECÍFICO PARA O ANTÍGENO, E UM COMPLEXO CD11b/CD18 HUMANO PARA UTILIZAÇÃO EM UM MÉTODO ANALÍTICOInfo
- Publication number
- BR112015028650A2 BR112015028650A2 BR112015028650A BR112015028650A BR112015028650A2 BR 112015028650 A2 BR112015028650 A2 BR 112015028650A2 BR 112015028650 A BR112015028650 A BR 112015028650A BR 112015028650 A BR112015028650 A BR 112015028650A BR 112015028650 A2 BR112015028650 A2 BR 112015028650A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- complex
- aureus
- leukocydin
- isolated
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 title abstract 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 title abstract 3
- 102100022338 Integrin alpha-M Human genes 0.000 title abstract 3
- 102100025390 Integrin beta-2 Human genes 0.000 title abstract 3
- 238000004458 analytical method Methods 0.000 title abstract 2
- 241000191967 Staphylococcus aureus Species 0.000 abstract 2
- 108010014603 Leukocidins Proteins 0.000 abstract 1
- 108010056995 Perforin Proteins 0.000 abstract 1
- 102000004503 Perforin Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
UM ANTÍGENO ISOLADO PARA LEUCOCIDINA DE S. AUREUS, UM ANTICORPO LIGANTE ESPECÍFICO PARA O ANTÍGENO, E UM COMPLEXO CD11B/CD18 HUMANO PARA UTILIZAÇÃO EM UM MÉTODO ANALÍTICO. A presente invenção se refere a um antígeno isolado para leucocidina de Staphylococcus aureus, compreendendo um complexo LukGH, um anticorpo que se liga especificamente ao complexo LukGH, e o complexo CD11b/CD18 humano para utilização em um método de determinação da ligação ou toxicidade da citolisina bicomponente LukGH de Staphylococcus aureus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13168631 | 2013-05-21 | ||
PCT/EP2014/060123 WO2014187746A2 (en) | 2013-05-21 | 2014-05-16 | Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015028650A2 true BR112015028650A2 (pt) | 2017-09-19 |
Family
ID=48470786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015028650A BR112015028650A2 (pt) | 2013-05-21 | 2014-05-16 | UM ANTÍGENO ISOLADO PARA LEUCOCIDINA DE S. AUREUS, UM ANTICORPO LIGANTE ESPECÍFICO PARA O ANTÍGENO, E UM COMPLEXO CD11b/CD18 HUMANO PARA UTILIZAÇÃO EM UM MÉTODO ANALÍTICO |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160108106A1 (pt) |
EP (1) | EP2999713A2 (pt) |
JP (2) | JP6560195B2 (pt) |
CN (1) | CN105473613A (pt) |
AU (1) | AU2014270598B2 (pt) |
BR (1) | BR112015028650A2 (pt) |
CA (1) | CA2913088A1 (pt) |
MX (1) | MX2015015965A (pt) |
RU (1) | RU2015154792A (pt) |
WO (1) | WO2014187746A2 (pt) |
ZA (1) | ZA201508287B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014336111A1 (en) * | 2013-10-17 | 2016-04-14 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody sequences |
RU2016129526A (ru) * | 2013-12-19 | 2018-01-24 | Арзанис Байэусайнсис ГмбХ | Антитело, выделенная нуклеиновая кислота, выделенный паратоп антитела, выделенный конформационный эпитоп, связывающая молекула, иммуноген, фармацевтический и диагностический препараты, лекарственная форма вакцины, способ лечения больного, подверженного риску или страдающего от инфекции Staphylococcus aureus, способ диагностики обнаружения инфекций Staphylococcus aureus и способ скрининга или анализа для определения связующего |
JP2018513168A (ja) | 2015-04-17 | 2018-05-24 | アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤 |
US11104724B2 (en) | 2016-05-23 | 2021-08-31 | New York University | Compositions and methods for antibodies targeting staphylococcal leukotoxins |
WO2018165089A1 (en) | 2017-03-06 | 2018-09-13 | Vanderbilt University | Human monoclonal antibodies to staphylococcus aureus lukab toxin |
AU2018285857B2 (en) | 2017-06-13 | 2022-10-06 | Abvacc, Inc. | Immunogenic compositions comprising Staphylococcus aureus leukocidin lukA and lukB derived polypeptides |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
WO2007145689A1 (en) * | 2006-06-12 | 2007-12-21 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
CN101535811B (zh) * | 2006-10-18 | 2016-05-04 | 生物梅里埃公司 | 用于体外诊断产pvl金黄色葡萄球菌的方法 |
CA2964398C (en) | 2007-09-14 | 2023-03-07 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
SI2445522T1 (sl) * | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
US8431687B2 (en) * | 2010-05-05 | 2013-04-30 | New York University | Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof |
DK3336225T3 (da) | 2010-07-16 | 2020-03-30 | Adimab Llc | Antistofbiblioteker |
PT2668208E (pt) * | 2012-04-17 | 2015-10-12 | Arsanis Biosciences Gmbh | Anticorpo de staphylococcus aureus de reação cruzada |
WO2013165613A1 (en) * | 2012-05-02 | 2013-11-07 | New York University | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
-
2014
- 2014-05-16 WO PCT/EP2014/060123 patent/WO2014187746A2/en active Application Filing
- 2014-05-16 MX MX2015015965A patent/MX2015015965A/es unknown
- 2014-05-16 CN CN201480038825.0A patent/CN105473613A/zh active Pending
- 2014-05-16 AU AU2014270598A patent/AU2014270598B2/en not_active Ceased
- 2014-05-16 EP EP14724466.9A patent/EP2999713A2/en not_active Withdrawn
- 2014-05-16 JP JP2016514343A patent/JP6560195B2/ja not_active Expired - Fee Related
- 2014-05-16 BR BR112015028650A patent/BR112015028650A2/pt not_active IP Right Cessation
- 2014-05-16 RU RU2015154792A patent/RU2015154792A/ru not_active Application Discontinuation
- 2014-05-16 CA CA2913088A patent/CA2913088A1/en not_active Abandoned
- 2014-05-16 US US14/892,925 patent/US20160108106A1/en not_active Abandoned
-
2015
- 2015-11-10 ZA ZA2015/08287A patent/ZA201508287B/en unknown
-
2019
- 2019-04-19 JP JP2019079807A patent/JP2019142921A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2999713A2 (en) | 2016-03-30 |
JP2019142921A (ja) | 2019-08-29 |
US20160108106A1 (en) | 2016-04-21 |
ZA201508287B (en) | 2017-01-25 |
AU2014270598A1 (en) | 2015-11-26 |
WO2014187746A3 (en) | 2015-03-12 |
CA2913088A1 (en) | 2014-11-27 |
JP6560195B2 (ja) | 2019-08-14 |
RU2015154792A (ru) | 2017-06-22 |
AU2014270598B2 (en) | 2018-09-20 |
CN105473613A (zh) | 2016-04-06 |
MX2015015965A (es) | 2016-07-11 |
WO2014187746A2 (en) | 2014-11-27 |
RU2015154792A3 (pt) | 2018-03-21 |
JP2016526033A (ja) | 2016-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015028650A2 (pt) | UM ANTÍGENO ISOLADO PARA LEUCOCIDINA DE S. AUREUS, UM ANTICORPO LIGANTE ESPECÍFICO PARA O ANTÍGENO, E UM COMPLEXO CD11b/CD18 HUMANO PARA UTILIZAÇÃO EM UM MÉTODO ANALÍTICO | |
BR112018071276A2 (pt) | anticorpos anti-il-33, composições, métodos e usos dos mesmos | |
CL2015002756A1 (es) | Moléculas fc biespecíficas | |
ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
BR112016007112A2 (pt) | Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação | |
BR112017009263A2 (pt) | anticorpo ou fragmento do mesmo que se liga a uma cd38 humana, anticorpo biespecífico, anticorpo ou fragmento do mesmo que se liga a cd38 humana e de cinomólgos, epítopo sobre a cd38 humana solúvel, composição e imunoconjugado | |
WO2014160160A3 (en) | Antibody drug conjugates and corresponding antibodies | |
BR112016025056A2 (pt) | uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica | |
BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
BR112016022841A8 (pt) | Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo | |
BR112017008945A2 (pt) | Anticorpos anti-cs1 e conjugados fármaco- anticorpo | |
BR112018012344A2 (pt) | anticorpos que se ligam especificamente a hla-dr e seus usos | |
MX2019012708A (es) | Anticuerpos teicoicos anti-pared y conjugados. | |
BR112019004995A2 (pt) | anticorpo que se liga especificamente a pd-1 e fragmento funcional do mesmo | |
BR112019004990A2 (pt) | anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo | |
MX369758B (es) | Anticuerpos anti-acido teicoico de pared y conjugados. | |
BR112016001782A2 (pt) | Proteína de fusão terapêutica | |
BR112015031710A2 (pt) | anticorpos para o receptor de ldl oxidada similar à lectina 1 e métodos de uso | |
BR112018072211A2 (pt) | anticorpos anti tl1a e utilizações dos mesmos | |
BR112017021779A2 (pt) | ?uma preparação combinada de anticorpos anti-staphylococcus aureus? | |
EP4079760A3 (en) | Antibodies against clostridium difficile toxins and methods of using the same | |
IL246160A0 (en) | Antibodies directed against the toxin (lukgh (lukab) of staphylococcus aureus and antibody sequences | |
MA38164A3 (fr) | Protéines de liaison à l'antigène anti-her3/her4 se liant à la boucle en épingle à cheveux beta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2566 DE 2020-03-10 |